AI-Enabled Biotech
Why we invest
Combining scientific insights, wet lab innovation, applied AI, and advanced analytics promises to revolutionize life sciences, including discovery, diagnostics, and drug development. The newest generation of technology in life science is unlocking novel approaches to cure intractable diseases and generating drugs with increased precision and effectiveness. New tech-enabling layers are supercharging scientists to accelerate early-stage discoveries and lowering barriers to clinical breakthroughs. Madrona partners with leading research institutions, like the UW’s Institute of Protein Design, the Fred Hutch Cancer Center, and Caltech, to help researchers translate their innovations into real-world impact. With decades of experience investing in AI/ML and working alongside partners from pharma to tech hyperscalers, Madrona helps founders bring their vision for a brighter future to life.
Nautilus Bio’s
Sujal Patel and Parag Mallick
on the proteome 
A-Alpha Bio’s
David Younger
on advancing drug discovery and the role of company culture 
Terray’s
Jacob Berlin
on why data is the difference for AI-driven drug development AI-Enabled Biotech
-
Modulus Therapeutics is a seed-stage cell therapy design studio developing an internal pipeline of NK cell anti-solid tumor programs. Failures in cell therapy efficacy can be traced to poor conceptualization, design and integration of engineered components. Modulus is uniting whole-cell synthetic biology with machine learning into a cell therapy design solution to dramatically reduce pipeline risk and accelerate the path to the clinic. The team is a diverse group of cell therapy veterans along with bioengineering and machine learning experts laser focused on driving therapeutic efficacy by accessing the full cell design space.Initial Investment2021Modulus Therapeutics is a seed-stage cell therapy design studio developing an internal pipeline of NK cell anti-solid tumor programs. Failures in cell therapy efficacy can be traced to poor conceptualization, design and integration of engineered components. Modulus is uniting whole-cell synthetic biology with machine learning into a cell therapy design solution to dramatically reduce pipeline risk and accelerate the path to the clinic. The team is a diverse group of cell therapy veterans along with bioengineering and machine learning experts laser focused on driving therapeutic efficacy by accessing the full cell design space.FoundersBryce Daines
Max DarnellInvestment JourneyAcquired by Ginkgo Bioworks
2024Initial Investment2021 -
Proof is a startup working to make powerful CRISPR-based molecular testing affordable and accessible to everyoneInitial Investment2020Proof is a startup working to make powerful CRISPR-based molecular testing affordable and accessible to everyoneFoundersFeng Zhang
Jonathan Gootenberg
Omar Abudayyeh
Siddharth ShenaiInvestment JourneyAcquired by Ginkgo Bioworks
2024Initial Investment2020